Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.
Lisinopril was granted FDA approval on 29 December 1987.
Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.
Northwestern University, Chicago, Illinois, United States
Creighton Community Health Center, Omaha, Nebraska, United States
GSK Investigational Site, Beloit, Wisconsin, United States
Hebrew SeniorLife, Boston, Massachusetts, United States
University of Southern California, Los Angeles, California, United States
Indiana University, Indianapolis, Indiana, United States
VA Palo Alto Health Care System, Palo Alto, California, United States
VA Medical Center, San Juan, San Juan, Puerto Rico
VA Medical Center, Memphis, Memphis, Tennessee, United States
University of Minnesota, Variety Club Research Center 102, Minneapolis, Minnesota, United States
GSK Investigational Site, Tacoma, Washington, United States
GSK Investigational Site, San Antonio, Texas, United States
St. Paul Heart Clinic, St. Paul, Minnesota, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.